The rapid adoption of GLP-1 therapies is transforming the treatment of Type 2 diabetes, while continuous glucose monitors (CGMs) are giving patients and healthcare providers unprecedented visibility into glucose management. But what happens when these two innovations are used together?

In this white paper, IQVIA MedTech explores findings from a newly published real-world study demonstrating that patients who combined GLP-1 therapy with CGM achieved faster and greater improvements in glycemic control than patients receiving GLP-1 therapy alone.

Drawing on one of the world's largest healthcare datasets, this analysis provides valuable evidence for pharmaceutical, diagnostics and medical device manufacturers looking to understand evolving treatment pathways, demonstrate product value, and generate evidence that supports commercial success.

What you'll learn after downloading this white paper, you'll discover:

• The latest evidence on the complementary use of GLP-1 therapies and continuous glucose monitoring in Type 2 diabetes.
• Key findings from a large retrospective study analysing more than 13,000 matched patients.
• Why earlier CGM adoption alongside GLP-1 therapy may accelerate improvements in HbA1c. 
• How real-world data can support evidence generation, market access and commercial strategy.